Some partnerships just make sense. Today we're proud to share that Viralgen is collaborating with #Gene2Cure Foundation, a nonprofit dedicated to advancing gene therapies for children with rare and ultra-rare genetic conditions.
Together, we'll be manufacturing a portfolio of investigational #AAV gene therapies using Aava™️, our proprietary platform.
As our CEO Jimmy Vanhove puts it: "Collaboration is central to advancing potential gene therapies for rare diseases." We couldn't agree more, and we're looking forward to working alongside the Gene2Cure team.
--> Read the full announcement here: viralgen.com/news/gene2cure…
#GeneTherapy #RareDisease #CDMO
Together, we'll be manufacturing a portfolio of investigational #AAV gene therapies using Aava™️, our proprietary platform.
As our CEO Jimmy Vanhove puts it: "Collaboration is central to advancing potential gene therapies for rare diseases." We couldn't agree more, and we're looking forward to working alongside the Gene2Cure team.
--> Read the full announcement here: viralgen.com/news/gene2cure…
#GeneTherapy #RareDisease #CDMO